Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evalua...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Gynecol Oncol
Hoofdauteurs: Rose, Peter G., Java, James J., Morgan, Mark A., Secord, Angeles Alvarez, Kesterson, Joshua P., Stehman, Frederick B., Warshal, David P., Creasman, William T., Hanjani, Parviz, Morris, Robert T., Copeland, Larry J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720165/
https://ncbi.nlm.nih.gov/pubmed/27692669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.09.005
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items